AU Patent

AU2019392904B9 — Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors

Assigned to University of Maryland Baltimore · Expires 2022-12-22 · 3y expired

What this patent protects

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

USPTO Abstract

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019392904B9
Jurisdiction
AU
Classification
—
Expires
2022-12-22
Drug substance claim
No
Drug product claim
No
Assignee
University of Maryland Baltimore
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.